Log In Get Started
Press Releases September 1, 2026 08:30 AM

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

CorMedix to Present at Wells Fargo 21st Annual Healthcare Conference

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
CRMD

CorMedix Therapeutics announced its senior management will participate in a fireside chat and investor meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8-10, 2026. A replay of the presentation will be available on the company's website.

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CRMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CorMedix will engage directly with investors and industry stakeholders at a major healthcare conference.
  • The company focuses on therapeutic products for life-threatening diseases primarily in institutional healthcare settings within the US.
  • The presentation provides an opportunity to update the market on developments and strategic initiatives.

PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026.

Wells Fargo 21st Annual Healthcare ConferenceDate:
Time:
Webcast:
Wednesday, September 9, 2026
12:45pm EDT
Click here
  

A replay of the fireside chat will also be available in the “Presentations and Events” page on the investor relations portion of the Company’s website at: www.cormedix.com

About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576


Risks

  • The company operates in the competitive and highly regulated biopharmaceutical sector, which carries development and regulatory approval risks.
  • Market reactions to conference presentations can be muted if no new material information is disclosed.
  • Commercial success depends on effective sales and marketing in hospital and clinical settings, which may be impacted by healthcare policy changes.

More from Press Releases

Skyworks Announces Extension of Expiration Date of Exchange Offers for Qorvo’s Senior Notes due 2029 and 2031 Sep 1, 2026 Quantumsphere Acquisition Corporation Announces Termination of the Agreement and Plan of Merger with SACH Pte. Ltd. Sep 1, 2026 Enovix’s TAA-Compliant Battery Manufacturing Strengthens Position with U.S. Defense Supply Chain Sep 1, 2026 Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange Sep 1, 2026 Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway Sep 1, 2026